English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The recognition of metabolic complications associated with the use of antiretroviral therapy (ART), including dyslipidemia, lipoatrophy, and dysregulation of glucose homeostasis, followed close on the heels of the introduction and widespread use of potent combination ART for the treatment of HIV infection. Our understanding of the role of specific drug classes and of individual antiretroviral agents in these metabolic disturbances has evolved over time and has helped to inform clinical care practices to both preventandtreatthesecomplications.Inthis issue of the Journal, Mallon et al. [1] present data that provide another important step forward in understanding the mechanismsoflipoatrophyinassociation with exposure to nucleoside reversetranscriptase inhibitors (NRTIs) and offer insight into why treatment with the peroxisome proliferator-activated receptor(PPAR)agonistshasoftenfailedto produce clinically significant gains in adipose tissue mass in trials involving HIVassociated lipoatrophy. The potential role of mitochondrial toxicity associated with NRTIs, in particular the potent effects of thymidine analogues (tNRTIs), was recognized early in the study of lipodystrophy and ART tox

the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases

Peroxisome Proliferator‐Activated Receptor γ Agonists and the Treatment of HIV‐Associated Lipoatrophy: Unraveling the Molecular Mechanism of Their Shortcomings